Matinas BioPharma Holdings Inc (MTNB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Matinas BioPharma Holdings Inc (MTNB) has a cash flow conversion efficiency ratio of -0.530x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.60 Million) by net assets ($3.02 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Matinas BioPharma Holdings Inc to measure how much of total assets are equity-financed.
Matinas BioPharma Holdings Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Matinas BioPharma Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how aggressively does Matinas BioPharma Holdings Inc reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Matinas BioPharma Holdings Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Matinas BioPharma Holdings Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
E-H.(CH)ENT. H. DL-00001
F:1VC
|
N/A |
|
METALQUEST MINING INC.
F:E7Q
|
0.085x |
|
Reliance Global Group Inc
NASDAQ:RELI
|
-0.077x |
|
Socket Mobile Inc
NASDAQ:SCKT
|
0.099x |
|
Nordic Asia Investment Group 1987 AB Series B
ST:NAIG-B
|
-0.087x |
|
Aquaporin AS
CO:AQP
|
-0.157x |
|
CT UK Capital And Income Investment Trust Plc
LSE:CTUK
|
0.024x |
|
Raja Ferry Port Public Company Limited
BK:RP
|
0.059x |
Annual Cash Flow Conversion Efficiency for Matinas BioPharma Holdings Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Matinas BioPharma Holdings Inc from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see MTNB market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $4.83 Million | $-7.01 Million | -1.452x | +30.64% |
| 2024-12-31 | $7.59 Million | $-15.88 Million | -2.093x | -163.64% |
| 2023-12-31 | $19.25 Million | $-15.28 Million | -0.794x | -51.82% |
| 2022-12-31 | $36.64 Million | $-19.16 Million | -0.523x | -80.29% |
| 2021-12-31 | $52.49 Million | $-15.22 Million | -0.290x | -6.42% |
| 2020-12-31 | $63.73 Million | $-17.37 Million | -0.273x | +36.08% |
| 2019-12-31 | $33.05 Million | $-14.09 Million | -0.426x | +33.32% |
| 2018-12-31 | $16.14 Million | $-10.32 Million | -0.639x | +40.40% |
| 2017-12-31 | $10.68 Million | $-11.46 Million | -1.073x | -25.36% |
| 2016-12-31 | $7.15 Million | $-6.12 Million | -0.856x | +33.50% |
| 2015-12-31 | $6.07 Million | $-7.81 Million | -1.287x | +63.99% |
| 2014-12-31 | $2.23 Million | $-7.96 Million | -3.573x | -1152.77% |
| 2013-12-31 | $10.47 Million | $-2.99 Million | -0.285x | -69.33% |
| 2012-12-31 | $339.94K | $-57.26K | -0.168x | -- |
About Matinas BioPharma Holdings Inc
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an… Read more